Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial

• Published in: Lancet neurology Vol. 19; no. 3; pp. 214 - 225
• Main Authors: Chataway, Jeremy, De Angelis, Floriana, Connick, Peter, Parker, Richard A, Plantone, Domenico, Doshi, Anisha, John, Nevin, Stutters, Jonathan, MacManus, David, Prados Carrasco, Ferran, Barkhof, Frederik, Ourselin, Sebastien, Braisher, Marie, Ross, Moira, Cranswick, Gina, Pavitt, Sue H, Giovannoni, Gavin, Gandini Wheeler-Kingshott, Claudia Angela, Hawkins, Clive, Sharrack, Basil, Bastow, Roger, Weir, Christopher J, Stallard, Nigel, Chandran, Siddharthan, Gandini Wheeler-Kingshott, Claudia A.M., Williams, Thomas, Beyene, Tiggy, Bassan, Vanessa, Zapata, Alvin, Lyle, Dawn, Cameron, James, Mollison, Daisy, Colville, Shuna, Dhillon, Baljean, Weir, Christopher J., Parker, Richard A., Gnanapavan, Sharmilee, Nicholas, Richard, Rashid, Waqar, Aram, Julia, Ford, Helen, Overell, James, Young, Carolyn, Arndt, Heinke, Duddy, Martin, Guadagno, Joe, Evangelou, Nikolaos, Craner, Matthew, Palace, Jacqueline, Hobart, Jeremy, Paling, David, Kalra, Seema, McLean, Brendan
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.03.2020; Elsevier Limited; Lancet Pub. Group
• Subjects: Administration, Oral; Adult; Amiloride; Amiloride - therapeutic use; Atrophy; Axon guidance; Brain; Clinical trials; Coronary artery; Coronary artery disease; Dementia; Disease Progression; Double-Blind Method; Double-blind studies; Drugs; Encephalomyelitis; Female; Fluoxetine; Fluoxetine - therapeutic use; Heart diseases; Humans; Huntingtons disease; Lung cancer; Magnetic Resonance Imaging; Male; Metabolism; Metastases; Middle Aged; Motor neurone disease; Multiple sclerosis; Multiple Sclerosis - drug therapy; Multiple Sclerosis, Chronic Progressive - drug therapy; Nervous system; Neurodegeneration; Neuroprotection; Neuroprotective Agents - therapeutic use; Parkinson's disease; Patients; Riluzole - therapeutic use; Subject heading schemes; Systematic review; Thrombosis; Treatment Outcome; United Kingdom > UK

Neurodegeneration is the pathological substrate that causes major disability in secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research identified three neuroprotective drugs acting on different axonal pathobiologies. We aimed to test the efficacy of these drugs in...